Market Expansion Digirad operates in nuclear medicine imaging with a diversified portfolio including Cardius, X-ACT+, CorCam, QuantumCam, and Ergo. The breadth across cardiac SPECT and general nuclear medicine suggests opportunities to upsell upgraded imaging systems, portable solutions, and attenuation correction features to existing customers and to imaging clinics looking to modernize legacy setups.

Acquisition Edge Past acquisitions (ATRM Holdings, Ultrascan) and the recent Digirad Health ownership change indicate an integration-focused growth path. This presents sales potential for bundled lifecycle services, cross-sell of service contracts, upgrades, and centralized maintenance through Catalyst MedTech’s nationwide support network.

Service Network Catalyst MedTech’s nationwide service and support infrastructure underpins Digirad’s value proposition. This can be leveraged to target clinics seeking reliable, long-term support for OEM imaging systems, offering extended warranties, remote monitoring, and planned downtime minimization plans.

Public Market Footnote Historical financial narrative shows revenue scale in the mid-market range with multiple plant assets and HoldCo strategy. Focus sales discussions on total cost of ownership, performance efficiency, and asset utilization to attract customers prioritizing predictable costs and modernization ROI.

Tech Modernization A pioneer in solid-state imaging with ongoing updates to Ergo and Cardius lines signals readiness to discuss latest imaging technology, software upgrades (Pardot/marketing tech aside), and integration with modern data workflows. Position offerings around enhanced image quality, accelerated workflows, and interoperability with hospital IT ecosystems.